Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

162 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

InvestigationalRegistered later-phase trial

Cancer type: Lung Cancer
Trial identifier: NCT07063745
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Metastatic Non-small Cell Lung Cancer With MTAP Deletion who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-23

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-23

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07063745 (opens in a new tab) (Clinical-trial registry) NCT07063745 Primary source NCT07063745
ClinicalTrials.gov — NCT07063745. NCT07063745.

Eligibility varies — review trial criteria.

Trial Watch: Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

InvestigationalRegistered later-phase trial

Cancer type: Breast Cancer
Trial identifier: NCT02115282
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-23

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-23

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT02115282 (opens in a new tab) (Clinical-trial registry) NCT02115282 Primary source NCT02115282
ClinicalTrials.gov — NCT02115282. NCT02115282.

Eligibility varies — review trial criteria.

Trial Watch: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

InvestigationalRegistered later-phase trial

Cancer type: Ovarian Cancer
Trial identifier: NCT02839707
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed: 2026-10-23

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-23

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT02839707 (opens in a new tab) (Clinical-trial registry) NCT02839707 Primary source NCT02839707
ClinicalTrials.gov — NCT02839707. NCT02839707.

Eligibility varies — review trial criteria.

Trial Watch: Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis

InvestigationalRegistered later-phase trial

Cancer type: Melanoma / Skin Cancer
Trial identifier: NCT07890415
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin, Melanoma in Situ, Carcinoma in Situ of Skin who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-23

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-23

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07890415 (opens in a new tab) (Clinical-trial registry) NCT07890415 Primary source NCT07890415
ClinicalTrials.gov — NCT07890415. NCT07890415.

Eligibility varies — review trial criteria.

Trial Watch: Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

InvestigationalRegistered later-phase trial

Cancer type: Leukemia
Trial identifier: NCT01886872
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 65 Years and older with Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-23

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-23

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT01886872 (opens in a new tab) (Clinical-trial registry) NCT01886872 Primary source NCT01886872
ClinicalTrials.gov — NCT01886872. NCT01886872.

Eligibility varies — review trial criteria.

Trial Watch: Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

InvestigationalRegistered later-phase trial

Cancer type: Brain / CNS Cancer, Sarcoma
Trial identifier: NCT02152982
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Glioblastoma, Gliosarcoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT02152982 (opens in a new tab) (Clinical-trial registry) NCT02152982 Primary source NCT02152982
ClinicalTrials.gov — NCT02152982. NCT02152982.

Eligibility varies — review trial criteria.

Trial Watch: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

InvestigationalRegistered later-phase trial

Cancer type: Kidney (Renal) Cancer
Trial identifier: NCT01575548
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7 who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT01575548 (opens in a new tab) (Clinical-trial registry) NCT01575548 Primary source NCT01575548
ClinicalTrials.gov — NCT01575548. NCT01575548.

Eligibility varies — review trial criteria.

Trial Watch: Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma

InvestigationalRegistered later-phase trial

Cancer type: Multiple Myeloma
Trial identifier: NCT07887984
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Multiple Myeloma (MM) who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07887984 (opens in a new tab) (Clinical-trial registry) NCT07887984 Primary source NCT07887984
ClinicalTrials.gov — NCT07887984. NCT07887984.

Eligibility varies — review trial criteria.

Trial Watch: The Cancer of the Pancreas Screening-5 CAPS5)Study

InvestigationalRegistered later-phase trial

Cancer type: Pancreatic Cancer
Trial identifier: NCT02000089
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT02000089 (opens in a new tab) (Clinical-trial registry) NCT02000089 Primary source NCT02000089
ClinicalTrials.gov — NCT02000089. NCT02000089.

Eligibility varies — review trial criteria.

Trial Watch: Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

InvestigationalRegistered later-phase trial

Cancer type: Endometrial (Uterine) Cancer
Trial identifier: NCT06486441
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Endometrial Cancer who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06486441 (opens in a new tab) (Clinical-trial registry) NCT06486441 Primary source NCT06486441
ClinicalTrials.gov — NCT06486441. NCT06486441.

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.